US Fact Sheet: Second Global Summit on COVID-19:

Prevent complacency and prioritize preparation

Today, the United States, Belize, Germany, Indonesia and Senegal invited other heads of state and world leaders from international organizations, the private sector, charities, NGOs and other partners for the Second Global Summit on COVID-19.

The United States has issued a call to redouble global efforts to control the COVID-19 pandemic and prepare for future health emergencies. The United States urged the world to prevent inaction and keep the political will strong. We have also called on leaders to accelerate financial and policy commitments – country by country, community by community – to fire at guns; expanding access to tests and treatments; protect people most at risk; and preventing future disasters by building and financing country capacity, health workers, disease surveillance, and medical countermeasures, including through the World Bank’s New Health Security Fund.

Vice President Harris highlighted US leadership and called on Congress to do so Continuing to make Americans and the world safer by immediately providing $22.5 billion in supplemental funding for the COVID-19 response requested by the administration on March 2, 2022, Including $5 billion to support the global effort To stop the spread of potential new variants, get injections in the arms, expand access to tests and treatments, and save lives here at home and abroad.

US leadership in vaccinating the world, saving lives, and building better health security

This summit continues to highlight US leadership in the global response to COVID-19. As the world’s largest donor, the United States has so far provided more than $19 billion in health, humanitarian, and economic assistance and has committed 1.2 billion doses of vaccine to the world free of charge, of which we have already provided more than 535 million doses.

At the summit, the United States called on the world to move along with co-hosts Belize, Germany, Indonesia and Senegal. Leaders from around the world have made bold new commitments to control COVID-19 and prevent future health crises. The United States has announced new commitments to the global response to COVID-19 and pandemic preparedness, building on the significant U.S. commitments made so far and during the recent COVID-19 Global Summit:

  • Additional funding for pandemic preparedness [and global health security] located in the World Bank. Building on its initial commitment of $250 million previously announced at the First Global COVID-19 Summit, the United States intends to increase its initial contribution toward the establishment of the new World Bank Pandemic Preparedness and Global Health Security Fund by an additional $200 million, for a total of 450 million dollars. Combined with funding pledged by other donors today, this funding provides at least $960 million in seed funding ahead of the fund’s launch this summer. The fund will provide sustainable financing to improve national, regional, and global capacities to prevent, detect, and respond to epidemics and other infectious disease threats.
  • Share US government research tools and intellectual property related to the COVID-19 vaccine to increase global reach. Through the National Institutes of Health (NIH), the United States recently licensed research tools and intellectual property for many COVID-19 technologies to the Drug Patent Collection, through the WHO’s COVID-19 Technology Access Pool. The licenses include a patent for the stabilized spike protein used in many of the current COVID-19 vaccines. These licenses will enable manufacturers from all over the world to use these technologies.
  • The United States, through the U.S. Food and Drug Administration (FDA), affirms its commitment to conduct comprehensive and effective reviews of response products to COVID-19. While COVID-19 remains a public health emergency, the Food and Drug Administration will prioritize review of COVID-19 treatments, including applications seeking initial approval for generic products. The Food and Drug Administration gives provisional approvals to products that meet FDA approval requirements but cannot be approved for reasons of exclusivity or patents.
  • Strategy and treatment testing. The United States, along with the Global Fund to Fight AIDS, Tuberculosis, and Malaria (“Global Fund”), Unitaid and other ACT-Accelerator partners, will promote “test and treat” strategies for the most vulnerable populations in middle-income countries to help prevent hospitalizations and deaths caused by COVID-19. The Global Fund will buy up to $80 million in rapid testing kits for COVID-19 and oral antiviral drugs, which will be tied to $20 million in US bailout bills that USAID plans to use to rapidly scale up testing and treatment implementation. in up to eight countries globally in 2022, in coordination with other US government programs, including PEPFAR. It will draw on an additional $22 million from Unitaid to produce an investment of more than $120 million to introduce testing and treatment strategies in more than 20 countries in 2022. This early collaborative investment will catalyze test and treatment adoption and expansion to additional countries.. This commitment is a down payment on US leadership that can be fully realized if Congress works to provide the supplemental funding the president has requested on COVID-19.
  • Additional vaccination support through Global VAX. Building on more than $1.7 billion in funds pledged to date, the United States, through the U.S. Centers for Disease Control and Prevention (CDC), is providing an additional $15 million to the U.S. Global Vaccine Initiative (Global VAX), As a whole – the government’s efforts to accelerate and expand uptake of vaccine readiness in countries with high needs, including 11 countries supporting the surge. This funding will enable the Centers for Disease Control and Prevention (CDC) to provide additional technical assistance and service delivery to countries for vaccination efforts, focusing on high-risk populations. This will build on the $1.7 billion the United States already provides through Global VAX.
  • Expand investments in bilateral programs for global health security. To advance the global health security agenda and accelerate the implementation of the US Global Health Security Strategy, the US government will expand the number of partner countries with extensive support for global health security by eight this year, including three new regions. This will improve countries’ capabilities to prevent, detect and respond to future COVID-19 variants and future health threats.
  • Expand the types of dose donations to include boosters and pediatric doses to accelerate global vaccine coverage. The United States is expanding the types of Pfizer vaccine doses donated globally to now include booster and pediatric doses, as part of our commitment to donate a billion Pfizer dose. This will help accelerate progress toward the 70% vaccination goal and expand the availability of doses available to those at higher risk and to children globally.
  • Improved guidance for vaccine development to enhance protection. The United States, through the Food and Drug Administration, is committed to helping harmonize global health authorities and the World Health Organization to advise producers of COVID-19 vaccines to report which strains they use as the basis for vaccines, using predictions about the dominance of future strains and which strains will lead to vaccines that provide the broadest protection against Unknown future variables.
  • Facility for financing COVID-19 vaccine and additional supply purchases and deliveries through the US International Development Finance Corporation (DFC). The DFC has created a vehicle to provide up to $1 billion to Gavi, the Vaccine Alliance, to provide bridging funding that secures commitments from other donors. This will allow COVAX to respond promptly in any crisis to procure and deliver additional supplies and vaccines on behalf of developing countries participating in the COVAX Advance Market Commitment.
  • Promote research and development of a COVID-19 vaccine through the Coalition for Epidemic Preparedness Innovations (CEPI). At least $50 million of the US government’s recent $150 million 3-year pledge to CEPI will support COVID-19 vaccine research as well as the development of other vaccines and countermeasures for future emerging infectious diseases, with goals of making vaccines preventative more widely and easier to use. Manage them in low-resource settings.

Despite these commitments to combat COVID-19 and strengthen future preparedness against health threatsThere is more work to be done to ensure the United States continues to lead, and to make Americans and the world safer. President Biden continues to urge Congress to act quickly to provide supplemental resources. Without additional emergency funding, the United States will not be able to purchase additional life-saving treatments for the American people. The United States will be less able to stop the spread of potential new variants from around the world. The United States will not be able to continue vaccinating the world against COVID-19 and gunfire, saving lives here at home and abroad.